Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;44(3):151222.
doi: 10.1016/j.semperi.2020.151222. Epub 2020 Jan 25.

Pharmacogenomics in pregnancy

Hannah K Betcher  1 , Alfred L George Jr  2
Affiliations
Review

Pharmacogenomics in pregnancy

Hannah K Betcher et al. Semin Perinatol. 2020 Apr.

Abstract

Pregnant women frequently take prescription and over the counter medications. The efficacy of medications is affected by the many physiological changes during pregnancy, and these events may be further impacted by genetic factors. Research on pharmacogenomic and pharmacokinetic influences on drug disposition during pregnancy has lagged behind other fields. Clinical investigators have demonstrated altered activity of several drug metabolizing enzymes during pregnancy. Emerging evidence also supports the influence of pharmacogenomic variability in drug response for many important classes of drugs commonly used in pregnancy. Prescribing medications during pregnancy requires an understanding of the substantial dynamic physiologic and metabolic changes that occur during gestation. Pharmacogenomics also contributes to the inter-individual variability in response to many medications, and more research is needed to understand how best to manage drug therapy in pregnant women.

Keywords: Drug metabolism; Drug therapy; Pharmacogenetics; Pharmacogenomics; Pregnancy.

PubMed Disclaimer

Conflict of interest statement

Disclosures: The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article.

References

    1. Giacomini KM, et al., The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther, 2007. 81(3): p. 328–45. - PMC - PubMed
    1. Muir AJ, et al., Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-alpha-based regimens. Clin Pharmacol Ther, 2014. 95(2): p. 141–6. - PMC - PubMed
    1. Crews KR, et al., Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther, 2014. 95(4): p. 376–82. - PMC - PubMed
    1. Martin MA, et al., Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update. Clin Pharmacol Ther, 2014. 95(5): p. 499–500. - PMC - PubMed
    1. Relling MV, et al., Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther, 2014. 96(2): p. 169–74. - PMC - PubMed

MeSH terms